MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

Press/Media

Period10 Jun 2022

Media coverage

2

Media coverage

  • TitleMorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date10/06/22
    PersonsJohn Mascarenhas
  • TitleDGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022 (english)
    Media name/outletdpa-AFX International ProFeed
    Country/TerritoryGermany
    Date10/06/22
    PersonsJohn Mascarenhas